Studies related to Cognitive Decline and Saffron

Comparing The Efficacy And Safety Of Crocus Sativus L. With Memantine In Patients With Moderate To Severe Alzheimer's Disease: A Double-blind Randomized Clinical Trial

Effect Decrease
Trial Design Randomized trial
Trial Length 6+ Months
Number of Subjects 68
Sex Both Genders
Age Range 45-64, 65+
Notes for this study:
In a randomized, double-blind, placebo-controlled trial, 68 participants with moderate to severe Alzheimer's disease took 30 mg of saffron extract or 20 mg of memantine daily for 12 months.

The primary outcome was score on the Severe Cognitive Impairment Rating Scale (SCIRS) and both groups saw a modest and comparable improvement over 12 months, though there wasn't a statistically significant difference from baseline. Score on the Functional Assessment Staging (FAST) saw an improvement and MiniMental State Examination also saw a comparable improvement.

The trial was preregistered: IRCT201203051556N39

Full details on all 2 studies are available to Examine Members. Try out the Examine Membership with a 14-day free trial.

Already a Member? Log in now to access.